Abstract: The present invention provides a disease model animal for tauopathies which reproduces the expression pattern of tau protein isoforms of adult human brain, that is, approximately equal amounts of 3R type tau and 4R type tau being expressed in the adult brain. The method for producing the disease model animal for tauopathies of the present invention comprises the steps of: preparing a tau seeds; and injecting the tau seeds in the brain of an animal carrying a mutation in the tau gene which fails to express the tenth exon. The animal carrying a mutation in the tau gene which fails to express the tenth exon may be produced by using any of the genome editing, gene targeting or base editing technologies.

Abstract: The present invention provides a disease model animal for tauopathies which reproduces the expression pattern of tau protein isoforms of adult human brain, that is, approximately equal amounts of 3R type tau and 4R type tau being expressed in the adult brain. The method for producing the disease model animal for tauopathies of the present invention comprises the steps of: preparing a tau seeds; and injecting the tau seeds in the brain of an animal carrying a mutation in the tau gene which fails to express the tenth exon. The animal carrying a mutation in the tau gene which fails to express the tenth exon may be produced by using any of the genome editing, gene targeting or base editing technologies.

Abstract: The present invention provides a hairless transgenic nonhuman animal used in the development of a therapy for dermatitis such as human atopic dermatitis and drug discovery. Specifically, the present invention provides a transgenic nonhuman animal, into which recombinant DNA comprising a heparin-binding EGF gene and a type 2 keratin gene promoter for regulating expression of the above gene has been introduced.

Abstract: The present invention relates to a diabetes animal model. Specifically, the present invention relates to a transgenic nonhuman animal, into which recombinant DNA comprising a gene encoding a diphtheria toxin receptor and an insulin promoter for regulating expression of the above gene has been introduced.

Abstract: A system for observing the behaviors of mitochondria during ontogeny and the dynamics of mitochondria in various tissues during pathological development is provided. A pCAGGS expression vector containing green fluorescent protein (GFP) gene and a transgenic animal characterized by expressing GFP specifically in mitochondria are provided.

Abstract: A system for observing the behaviors of mitochondria during ontogeny and the dynamics of mitochondria in various tissues during pathological development is provided. A pCAGGS expression vector containing green fluorescent protein (GFP) gene and a transgenic animal characterized by expressing GFP specifically in mitochondria are provided.